PAMU
ALLO icon

Pictet Asset Management (UK)’s Allogene Therapeutics ALLO Stock Holding History

Pictet Asset Management (UK)’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-239,024
Closed -$6.42M – 1016
2019
Q2 		$6.42M Hold
239,024
– – 0.01% 635
2019
Q1 		$6.91M Sell
239,024
-59,953
-20% -$1.74M 0.02% 623
2018
Q4 		$8.05K Buy
+298,977
New +$7.94M 0.02% 540

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pictet Asset Management (UK)'s ALLO Position: Q3 2019 in Review

Pictet Asset Management (UK) sold out of Allogene Therapeutics (ALLO) in Q3 2019, closing a stake of 239,024 shares — an estimated $6.42M sold.

Pictet Asset Management (UK) first reported a position in ALLO in Q4 2018 and held it in 3 quarters. The position peaked at $6.91M in Q1 2019. 95 funds tracked by Wall St. Rank hold ALLO as of Q3 2019.

  • Pictet Asset Management (UK) reported no remaining Allogene Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Pictet Asset Management (UK) sold 239,024 Allogene Therapeutics shares in Q3 2019, an estimated $6.42M.
  • Pictet Asset Management (UK) first reported a position in Allogene Therapeutics in Q4 2018 and held it in 3 quarters.
  • Pictet Asset Management (UK)'s Allogene Therapeutics position peaked at $6.91M in Q1 2019.
  • 95 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2019.

Based on Pictet Asset Management (UK)'s 13F filing for Q3 2019, filed 14 Nov 2019.